Skip to main content

Table 3 Allogenic Stem Cell Transplantation (HSCT) use

From: Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden of disease - A population-based study

Characteristics

Familial screen cases (N = 10)

Index cases (N = 9)

Total (N = 19)

Allo-HSCT

    

Age at 1st HSCT (y)

median

(Q1-Q3)

7.0 (6.0–10.0)

8.0 (7.0–10.0)

7.0 (6.0–10.0)

Time between diagnosis and HSCT (months)

10.3 (3.0–51.4)

4.9 (1.4–9.2)

4.9 (1.4–19.9)